The company raised its full-year revenue, VOXZOGO revenue and non-GAAP diluted earnings-per-share guidance, though it did not provide updated ranges during the call. The company expects approximately $220 million in annual run-rate cost synergies to be fully realized in 2028, representing about a 50% reduction from Amicus’ 2025 non-GAAP operating expenses of $432 million. BioMarin expects substantial earnings accretion to begin in 2027, with roughly half to slightly more than half of the planned synergies expected to be realized next year. BioMarin expects both patient additions and ordering patterns to lift VOXZOGO revenue in the second half compared with the first half. About BioMarin Pharmaceutical (NASDAQ:BMRN)BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases.